EUCTR2014-005378-12-BG进行中（未招募）1 期
Efficacy and Safety of Fixed-Dose Combination atorvastatin/amlodipine/perindopril versus Fixed-Dose Combination of atorvastatin/ amlodipine in Patients with Hypertension and Dyslipidemia.
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 830
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1- Men or women of any ethnic origin aged 40 to 79 years inclusive who have signed the informed consent form and can comply with the study requirements and timetable.
- •2- Essential hypertension defined as:
- •-Hypertensive patients naïve of treatment with 160 mmHg = SBP <180 mmHg and 100 mmHg = DBP < 110 mmHg or isolated systolic hypertension (160 mmHg = SBP <180 mmHg and DBP < 100 mmHg)) or
- •-Uncontrolled hypertensive patients currently under monotherapy treatment within at least 4 weeks (except patients treated by perindopril 10mg or amlodipine 10mg) for combined systolic and diastolic hypertension (150 mmHg = SBP < 180 mmHg and 95 mmHg = DBP < 110 mmHg) or isolated systolic hypertension (150 mmHg = SBP < 180 mmHg and DBP < 95 mmHg)),
- •3- Dysplipidemic patients : naïve of treatment or uncontrolled with statin at lowest dose within at least 4 weeks with 130 mg/ Decilitre (dL) (or 3.36 millimole [mmol] /L) = LDL-c < 190 mg/dL (or 4.91 mmol/L) according to a prevous laboratory result within 12 months
- •4- Confirmed hypertension measured at inclusion: 150 mmHg = SBP < 180 mmHg and 95 mmHg = DBP < 110 mmHg or isolated systolic hypertension 150 mmHg = SBP < 180 mmHg and DBP < 95 mm Hg for either patients under prior monotherapy treatment or patients naive of treatment
- •5- Confirmed dyslipidemia on lipid profile assessed at W0 visit: 130 mg/dL = LDL-c < 190 mg/dL.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 623
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 207
排除标准
- •1- Known symptomatic orthostatic hypotension
- •2- Secondary hypertension
- •3- Isolated diastolic hypertension defined as DBP > or = 90 mmHg
- •4- Known complicated hypertension: known stage III or IV hypertensive retinopathy, microalbuminaria
- •5- Known diabetes mellitus type I or type II
- •6- Obesity defined as a body mass index = 32 kg/m2
- •7- History or current presence of lymphedema or leg edema (unilateral or bilateral) of venous origin: previously known or discovered during the clinical examination at the selection visit, due to but not limited to calcium channel blockers, especially amlodipine (which induced amlodipine dose down titration or treatment stop)
- •8- Any history of stroke, transient ischemic attack, cerebrovascular surgery or history of coronary artery disease; heart failure (New York Heart Association [NYHA] II-IV), or hypertrophic obstructive myocardiopathy; unstable angina
- •9- Known ventricular rhythm disorders (except premature ventricular extrasystole less frequent than 6/minute); history of atrial fibrillation or atrial flutter (except if cured e.g. ablation without no new episodes within the last 12 months) or second or third degree A-V block or other cardiac rhythm disorders leading to important beat to beat variations in blood pressure or known valvular diseases (except mitral valve prolapse)
- •10- Known renal impairment moderate or severe (known creatinine clearance <60 mL/mn), or bilateral renal artery stenosis or stenosis to a solitary kidney.
- •11- Contraindications to calcium channel inhibitors and/or to ACE inhibitors and/or to statins and especially: known allergy/hypersensitivity/history of intolerance, muscular toxicity during a treatment with a statin, hereditary or idiopathic
- •angioedema, or history of angioedema associated with previous ACE inhibitor therapy.
- •12- Any other medication which may be used for the treatment of hypertension, but which is currently being taken by the patient for an alternative indication, and which cannot be discontinued at the selection visit.
- •13- History of myopathy, familial history of hereditary muscular disorders.
研究者
相似试验
进行中（未招募）
1 期
Efficacy and Safety of Fixed-Dose Combinationatorvastatin / amlodipine / perindopril versus Fixed-Dose Combination of atorvastatin / amlodipine in Patients with Hypertension and Dyslipidemia.Hypertension and dyslipidemiaMedDRA version: 20.0Level: HLTClassification code 10020774Term: Vascular hypertensive disorders NECSystem Organ Class: 100000004866MedDRA version: 21.0Level: LLTClassification code 10058110Term: DyslipidemiaSystem Organ Class: 100000004861EUCTR2014-005378-12-ITINSTITUT DE RECHERCHES INTERNATIONALES SERVIER854
已完成
4 期
Efficacy and Safety Study Tablet ( Irpo- FA®) in Pregnant WomeIron Deficiency & Folic acid Deficiency anemia.Iron deficiency anaemia, unspecified & Folate deficiency anaemia, unspecifiedD-50 & D-5IRCT201610197978N3abiqasim Industries (Pvt) Ltd.50
已完成
3 期
Safety and Efficacy Study of Fixed Dose Combination of Three Antidiabetic Drugs in Comparison to Two Antidiabetic Drugs in Patients with Type 2 DiabetesCTRI/2016/11/007439Sun Pharma Laboratories Limited301
已完成
3 期
A clinical trial to study the efficacy and safety of combination drugs of chlorthalidone, metoprolol and telmisartan in treatment of high blood pressure with stable coronary artery disease.CTRI/2016/11/007491Sun Pharma Laboratories Limited254
已完成
3 期
A clinical study to evaluate the effects of Fixed Dose Combination of 2 drugs, Indapamide S.R. (1.5 mg) + Amlodipine (5 mg) in patients with high blood pressureCTRI/2010/091/000114Serdia Pharmaceuticals India Pvt Ltd240